Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up
To evaluate the duration of topical brimonidine therapy before the onset of brimonidine-related allergic conjunctivitis and the clinical characteristics associated with the development of brimonidine allergy.We retrospectively enrolled patients who presented brimonidine allergy from December 1, 2008...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2021-07, Vol.100 (29), p.e26724-e26724 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e26724 |
|---|---|
| container_issue | 29 |
| container_start_page | e26724 |
| container_title | Medicine (Baltimore) |
| container_volume | 100 |
| creator | Yeh, Po-Han Cheng, Yu-Chun Shie, Shian-Sen Lee, Yung-Sung Shen, Su-Chin Chen, Henry Shen-Lih Wu, Wei-Chi Su, Wei-Wen |
| description | To evaluate the duration of topical brimonidine therapy before the onset of brimonidine-related allergic conjunctivitis and the clinical characteristics associated with the development of brimonidine allergy.We retrospectively enrolled patients who presented brimonidine allergy from December 1, 2008 to November 30, 2020. The duration of brimonidine treatment, concomitant medications, benzalkonium chloride (BAK) exposure, change in IOP, and season of onset were evaluated.292 patients were included, among which 147 were female and 145 were male. The mean age was 58.3 ± 13.6 years old. The mean (median) duration of brimonidine therapy was 266.6 (196) days, with a peak at 60-120 days. The duration was similar whether the patients received brimonidine monotreatment or in combination with other glaucoma drugs, with or without BAK. The IOP increased by 5.6% after brimonidine allergy (P |
| doi_str_mv | 10.1097/MD.0000000000026724 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8294862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2561924038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3558-6c406a49282f4215cd5235c50a14975ef3f52c6fbf0c672705ca2697a8d08e7e3</originalsourceid><addsrcrecordid>eNpdkV1PFTEQhhsjkSP6C0xML71wsdvPrRcmCn6QQLjR66Z0ZznFbntou5z47y0cRGVuJpk-885MX4Re9eSwJ1q9Ozs-JH-DSkX5E7TqBZOd0JI_RatWFZ3Siu-j56VcEdKzBj1D-4wzPRAuV-j6U_Zzin70EXCGYCuM2LqlAp5SCN4twWbsUrxaoqv-xldf3uPzWKDi6mfANo7YBR-9swFvMhSI1VafYnmLLQ4pXnYV8nynlrbdsnmB9iYbCry8zwfox5fP34--dafnX0-OPp52jgkxdNJxIi3XdKATp71wo6BMOEFsz7USMLFJUCeni4m4droiwlkqtbLDSAZQwA7Qh53uZrmYYXRtr2yD2bR7bf5lkvXm_5fo1-Yy3ZiBaj5I2gTe3AvkdL1AqWb2xUEINkJaiqFC9ppywoaGsh3qciolw_Qwpifm1ixzdmwem9W6Xv-74UPPH3cawHfANoX2ieVnWLaQzRpsqOs7PaE07SihPVGUka5V-MB-A8YGoX8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2561924038</pqid></control><display><type>article</type><title>Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yeh, Po-Han ; Cheng, Yu-Chun ; Shie, Shian-Sen ; Lee, Yung-Sung ; Shen, Su-Chin ; Chen, Henry Shen-Lih ; Wu, Wei-Chi ; Su, Wei-Wen</creator><creatorcontrib>Yeh, Po-Han ; Cheng, Yu-Chun ; Shie, Shian-Sen ; Lee, Yung-Sung ; Shen, Su-Chin ; Chen, Henry Shen-Lih ; Wu, Wei-Chi ; Su, Wei-Wen</creatorcontrib><description>To evaluate the duration of topical brimonidine therapy before the onset of brimonidine-related allergic conjunctivitis and the clinical characteristics associated with the development of brimonidine allergy.We retrospectively enrolled patients who presented brimonidine allergy from December 1, 2008 to November 30, 2020. The duration of brimonidine treatment, concomitant medications, benzalkonium chloride (BAK) exposure, change in IOP, and season of onset were evaluated.292 patients were included, among which 147 were female and 145 were male. The mean age was 58.3 ± 13.6 years old. The mean (median) duration of brimonidine therapy was 266.6 (196) days, with a peak at 60-120 days. The duration was similar whether the patients received brimonidine monotreatment or in combination with other glaucoma drugs, with or without BAK. The IOP increased by 5.6% after brimonidine allergy (P < .001), which was even higher in the brimonidine monotherapy group (9.2%, P < .001). There was no significant IOP elevation in patients treated with multiple glaucoma medications.Around half of brimonidine allergy occurred within 6 months, with a peak in 2 to 4 months. The duration did not differ in patients receiving brimonidine monotherapy or multiple glaucoma medications. The presence of BAK did not affect the duration either. When brimonidine allergy occurred, there was a loss of IOP control, especially in patients receiving brimonidine monotherapy. It is recommended to switch to other types of glaucoma medications for better IOP control.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000026724</identifier><identifier>PMID: 34398046</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - adverse effects ; Brimonidine Tartrate - administration & dosage ; Brimonidine Tartrate - adverse effects ; Conjunctivitis, Allergic - chemically induced ; Conjunctivitis, Allergic - epidemiology ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Glaucoma - drug therapy ; Humans ; Intraocular Pressure ; Longitudinal Studies ; Male ; Middle Aged ; Observational Study ; Ophthalmic Solutions - administration & dosage ; Ophthalmic Solutions - adverse effects ; Retrospective Studies</subject><ispartof>Medicine (Baltimore), 2021-07, Vol.100 (29), p.e26724-e26724</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3558-6c406a49282f4215cd5235c50a14975ef3f52c6fbf0c672705ca2697a8d08e7e3</cites><orcidid>0000-0002-2755-8165</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294862/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294862/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34398046$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yeh, Po-Han</creatorcontrib><creatorcontrib>Cheng, Yu-Chun</creatorcontrib><creatorcontrib>Shie, Shian-Sen</creatorcontrib><creatorcontrib>Lee, Yung-Sung</creatorcontrib><creatorcontrib>Shen, Su-Chin</creatorcontrib><creatorcontrib>Chen, Henry Shen-Lih</creatorcontrib><creatorcontrib>Wu, Wei-Chi</creatorcontrib><creatorcontrib>Su, Wei-Wen</creatorcontrib><title>Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>To evaluate the duration of topical brimonidine therapy before the onset of brimonidine-related allergic conjunctivitis and the clinical characteristics associated with the development of brimonidine allergy.We retrospectively enrolled patients who presented brimonidine allergy from December 1, 2008 to November 30, 2020. The duration of brimonidine treatment, concomitant medications, benzalkonium chloride (BAK) exposure, change in IOP, and season of onset were evaluated.292 patients were included, among which 147 were female and 145 were male. The mean age was 58.3 ± 13.6 years old. The mean (median) duration of brimonidine therapy was 266.6 (196) days, with a peak at 60-120 days. The duration was similar whether the patients received brimonidine monotreatment or in combination with other glaucoma drugs, with or without BAK. The IOP increased by 5.6% after brimonidine allergy (P < .001), which was even higher in the brimonidine monotherapy group (9.2%, P < .001). There was no significant IOP elevation in patients treated with multiple glaucoma medications.Around half of brimonidine allergy occurred within 6 months, with a peak in 2 to 4 months. The duration did not differ in patients receiving brimonidine monotherapy or multiple glaucoma medications. The presence of BAK did not affect the duration either. When brimonidine allergy occurred, there was a loss of IOP control, especially in patients receiving brimonidine monotherapy. It is recommended to switch to other types of glaucoma medications for better IOP control.</description><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Brimonidine Tartrate - administration & dosage</subject><subject>Brimonidine Tartrate - adverse effects</subject><subject>Conjunctivitis, Allergic - chemically induced</subject><subject>Conjunctivitis, Allergic - epidemiology</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glaucoma - drug therapy</subject><subject>Humans</subject><subject>Intraocular Pressure</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Observational Study</subject><subject>Ophthalmic Solutions - administration & dosage</subject><subject>Ophthalmic Solutions - adverse effects</subject><subject>Retrospective Studies</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV1PFTEQhhsjkSP6C0xML71wsdvPrRcmCn6QQLjR66Z0ZznFbntou5z47y0cRGVuJpk-885MX4Re9eSwJ1q9Ozs-JH-DSkX5E7TqBZOd0JI_RatWFZ3Siu-j56VcEdKzBj1D-4wzPRAuV-j6U_Zzin70EXCGYCuM2LqlAp5SCN4twWbsUrxaoqv-xldf3uPzWKDi6mfANo7YBR-9swFvMhSI1VafYnmLLQ4pXnYV8nynlrbdsnmB9iYbCry8zwfox5fP34--dafnX0-OPp52jgkxdNJxIi3XdKATp71wo6BMOEFsz7USMLFJUCeni4m4droiwlkqtbLDSAZQwA7Qh53uZrmYYXRtr2yD2bR7bf5lkvXm_5fo1-Yy3ZiBaj5I2gTe3AvkdL1AqWb2xUEINkJaiqFC9ppywoaGsh3qciolw_Qwpifm1ixzdmwem9W6Xv-74UPPH3cawHfANoX2ieVnWLaQzRpsqOs7PaE07SihPVGUka5V-MB-A8YGoX8</recordid><startdate>20210723</startdate><enddate>20210723</enddate><creator>Yeh, Po-Han</creator><creator>Cheng, Yu-Chun</creator><creator>Shie, Shian-Sen</creator><creator>Lee, Yung-Sung</creator><creator>Shen, Su-Chin</creator><creator>Chen, Henry Shen-Lih</creator><creator>Wu, Wei-Chi</creator><creator>Su, Wei-Wen</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2755-8165</orcidid></search><sort><creationdate>20210723</creationdate><title>Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up</title><author>Yeh, Po-Han ; Cheng, Yu-Chun ; Shie, Shian-Sen ; Lee, Yung-Sung ; Shen, Su-Chin ; Chen, Henry Shen-Lih ; Wu, Wei-Chi ; Su, Wei-Wen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3558-6c406a49282f4215cd5235c50a14975ef3f52c6fbf0c672705ca2697a8d08e7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Brimonidine Tartrate - administration & dosage</topic><topic>Brimonidine Tartrate - adverse effects</topic><topic>Conjunctivitis, Allergic - chemically induced</topic><topic>Conjunctivitis, Allergic - epidemiology</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glaucoma - drug therapy</topic><topic>Humans</topic><topic>Intraocular Pressure</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Observational Study</topic><topic>Ophthalmic Solutions - administration & dosage</topic><topic>Ophthalmic Solutions - adverse effects</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yeh, Po-Han</creatorcontrib><creatorcontrib>Cheng, Yu-Chun</creatorcontrib><creatorcontrib>Shie, Shian-Sen</creatorcontrib><creatorcontrib>Lee, Yung-Sung</creatorcontrib><creatorcontrib>Shen, Su-Chin</creatorcontrib><creatorcontrib>Chen, Henry Shen-Lih</creatorcontrib><creatorcontrib>Wu, Wei-Chi</creatorcontrib><creatorcontrib>Su, Wei-Wen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yeh, Po-Han</au><au>Cheng, Yu-Chun</au><au>Shie, Shian-Sen</au><au>Lee, Yung-Sung</au><au>Shen, Su-Chin</au><au>Chen, Henry Shen-Lih</au><au>Wu, Wei-Chi</au><au>Su, Wei-Wen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2021-07-23</date><risdate>2021</risdate><volume>100</volume><issue>29</issue><spage>e26724</spage><epage>e26724</epage><pages>e26724-e26724</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>To evaluate the duration of topical brimonidine therapy before the onset of brimonidine-related allergic conjunctivitis and the clinical characteristics associated with the development of brimonidine allergy.We retrospectively enrolled patients who presented brimonidine allergy from December 1, 2008 to November 30, 2020. The duration of brimonidine treatment, concomitant medications, benzalkonium chloride (BAK) exposure, change in IOP, and season of onset were evaluated.292 patients were included, among which 147 were female and 145 were male. The mean age was 58.3 ± 13.6 years old. The mean (median) duration of brimonidine therapy was 266.6 (196) days, with a peak at 60-120 days. The duration was similar whether the patients received brimonidine monotreatment or in combination with other glaucoma drugs, with or without BAK. The IOP increased by 5.6% after brimonidine allergy (P < .001), which was even higher in the brimonidine monotherapy group (9.2%, P < .001). There was no significant IOP elevation in patients treated with multiple glaucoma medications.Around half of brimonidine allergy occurred within 6 months, with a peak in 2 to 4 months. The duration did not differ in patients receiving brimonidine monotherapy or multiple glaucoma medications. The presence of BAK did not affect the duration either. When brimonidine allergy occurred, there was a loss of IOP control, especially in patients receiving brimonidine monotherapy. It is recommended to switch to other types of glaucoma medications for better IOP control.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>34398046</pmid><doi>10.1097/MD.0000000000026724</doi><orcidid>https://orcid.org/0000-0002-2755-8165</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2021-07, Vol.100 (29), p.e26724-e26724 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8294862 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wolters Kluwer Open Health; IngentaConnect Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antihypertensive Agents - administration & dosage Antihypertensive Agents - adverse effects Brimonidine Tartrate - administration & dosage Brimonidine Tartrate - adverse effects Conjunctivitis, Allergic - chemically induced Conjunctivitis, Allergic - epidemiology Drug Administration Schedule Female Follow-Up Studies Glaucoma - drug therapy Humans Intraocular Pressure Longitudinal Studies Male Middle Aged Observational Study Ophthalmic Solutions - administration & dosage Ophthalmic Solutions - adverse effects Retrospective Studies |
| title | Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T11%3A09%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brimonidine%20related%20acute%20follicular%20conjunctivitis:%20Onset%20time%20and%20clinical%20presentations,%20a%20long-term%20follow-up&rft.jtitle=Medicine%20(Baltimore)&rft.au=Yeh,%20Po-Han&rft.date=2021-07-23&rft.volume=100&rft.issue=29&rft.spage=e26724&rft.epage=e26724&rft.pages=e26724-e26724&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000026724&rft_dat=%3Cproquest_pubme%3E2561924038%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2561924038&rft_id=info:pmid/34398046&rfr_iscdi=true |